These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 16433184)

  • 1. [Vancomycin-resistant Staphylococcus aureus].
    Rodríguez CA; Vesga O
    Biomedica; 2005 Dec; 25(4):575-87. PubMed ID: 16433184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vancomycin resistance in Staphylococcus aureus.
    Appelbaum PC; Bozdogan B
    Clin Lab Med; 2004 Jun; 24(2):381-402. PubMed ID: 15177846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
    Appelbaum PC
    Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Searching for Staphylococcus aureus strains with reduced susceptibility to glycopeptides among clinical isolates obtained during the year of 2002].
    Młynarczyk A; Młynarczyk G; Łuczak M
    Med Dosw Mikrobiol; 2003; 55(3):209-17. PubMed ID: 14702662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
    Fritsche TR; Rhomberg PR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a vancomycin intermediate-resistant Staphylococcus aureus isolated from a hospital.
    Mirani ZA; Jamil N
    J Coll Physicians Surg Pak; 2010 Aug; 20(8):558-9. PubMed ID: 20688028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates].
    Hoşgör Limoncu M; Ermertcan S; Taşli H; Kurutepe S
    Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.
    Garnier F; Chainier D; Walsh T; Karlsson A; Bolmström A; Grelaud C; Mounier M; Denis F; Ploy MC
    J Antimicrob Chemother; 2006 Jan; 57(1):146-9. PubMed ID: 16286482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
    Sakoulas G; Moellering RC
    Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus.
    Ruef C
    Infection; 2004 Dec; 32(6):315-27. PubMed ID: 15597220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2000 Jan; 48(51-52):1165-7. PubMed ID: 11266244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
    Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
    Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Soriano A; Marco F; Martínez JA; Pisos E; Almela M; Dimova VP; Alamo D; Ortega M; Lopez J; Mensa J
    Clin Infect Dis; 2008 Jan; 46(2):193-200. PubMed ID: 18171250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).
    Howden BP
    Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staphylococcus aureus resistant to vancomycin--United States, 2002.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Jul; 51(26):565-7. PubMed ID: 12139181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin.
    Rybak MJ; Cha R; Cheung CM; Meka VG; Kaatz GW
    Diagn Microbiol Infect Dis; 2005 Feb; 51(2):119-25. PubMed ID: 15698717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.
    Fridkin SK; Hageman J; McDougal LK; Mohammed J; Jarvis WR; Perl TM; Tenover FC;
    Clin Infect Dis; 2003 Feb; 36(4):429-39. PubMed ID: 12567300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of severe infections caused by Staphylococcus aureus: a change in the vancomycin paradigm?
    Aranha Camargo LF
    Shock; 2008 Oct; 30 Suppl 1():67-9. PubMed ID: 18704006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.